EFFICACY AND SAFETY OF TOPIRAMATE IN THE TREATMENT OF REFRACTORY EPILEPSY IN INFANTS AND YOUNG CHILDREN: A MULTI-CENTER STUDY

Kishore kumar C; Swetha Kesamreddy; Usha Rani Hasthi

doi:10.48047/3d4gbc03

Authors

Dr. Kishore kumar C1 Assistant Professor, Dept of Paediatrics, Sri Lakshmi Narayana Institute of Medical Science Medical Sciences, Pondicherry, India. Author
Dr. Swetha Kesamreddy Associate Professor, Dept of Paediatrics, Swamy Vivekananda institute of medical sciences Tiruchengode, Tamilnadu, India. Author
Dr. Usha Rani Hasthi Associate Professor, Dept of Paediatrics, Swamy Vivekananda institute of medical sciences Tiruchengode, Tamilnadu, India. Author

DOI:

https://doi.org/10.48047/3d4gbc03

Keywords:

Topiramate, refractory epilepsy, Lennox-Gastaut syndrome, infantile spasms, pediatric epilepsy

Abstract

Topiramate is a novel antiepileptic drug (AED) that has demonstrated that efficiency in this management of a variety of refractory epilepsy in children. The hypothesis of this research was to determine the safety and efficacy of topiramate on children of 60 months and below in age who were in infancy and refused epilepsy composed of Lennox-Gastaut syndrome (LGS), infantile spasms (IS), and more other epileptic disorders. This was a multi-center study in which 65 children were involved. The outcomes revealed that topiramate was tolerable and efficacious in decreasing the amount of seizures, and an enormous percentage of children got full remission or over 50 percent decrease in seizure rate. Somnolence, reduced appetite, and behavior change were typical side effects, but the level was mild and did not last long. Children with cryptogenic and LGS related epilepsy showed better response to treatment whereas symptomatic epilepsy exhibited low response. Although the results are promising, there are safety and toxicity issues that must be resolved because metabolic changes and cognitive effects were not the subject of the study. There must be additional research to access the effectiveness of topiramate in long-term based mostly in relation to the cognitive developments and metabolic actions within young children.

Downloads

Download data is not yet available.

References

Shank, R.P., Gardocki, J.F., Streeter, A.J. An overview of the preclinical aspects of topiramate, pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41:S21-S24.

White, H.S., Brown, S.D., Woodhead, J.H. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41:S17-S20.

Gibbs, J.W., Sombati, S., DeLorenzo, R.J. Cellular action of topiramate: blockade of kainite-evoked inward current in cultured hippocampal neurons. Epilepsia. 2000;41:S10-S16.

Biton, V., Montouris, G.D., Ritter, F. A randomized placebo-controlled study of topiramate in primary generalized tonic clonic seizures. Neurology. 1999;52:1330-1337.

Faught, E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia. 1997;38:S24-S27.

Ben-Menachem, E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia. 1997;38:S28-S30.

Mikaeloff, Y., de Saint-Martin, A., Mancini, J. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res. 2003;53:225-232.

Coppola, G., Caliendo, G., Veggiotti, P. Topiramate in refractory partial onset seizures in children, adolescents, and young adults: a multicentric open trial. Epilepsy Res. 2001;43:255-260.

Holland, K., Wyllie, E. Use of topiramate in localization-related epilepsy in children. J Child Neurol. 2000;15:S3-S6.

Wheless, J.W. Use of topiramate in childhood generalized seizure disorders. J Child Neurol. 2000;15:S7-S13.

Glauser, T.A., Clark, P.O., Strawsburg, R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia. 1998;39:1324-1328.

Thiji, J., Verhelst, H., Vancoster, R. Retrospective study of topiramate in a pediatric population with intractable epilepsy showing promising effects in the west syndrome patients. Acta Neurol Belg. 2001;101:171-176.

Watemberg, N., Goldberg-Stern, H., Ben-Zeev, B. Clinical experience with open label topiramate use in infants younger than 2 years of age. J Child Neurol. 2003;258-262.

Sachdeo, R.C., Glauser, T.A., Ritter, F. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology. 1999;52:1882-1887.

Coppola, G., Caliendo, G., Veggiotti, P. Topiramate as add-on drug in children, adolescent, and young adult with Lennox–Gastaut syndrome: an Italian multicentric study. Epilepsy Res. 2002;51:147-153.

Alva-Moncayo, E., Ruiz-Ruiz, A. The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox–Gastaut syndrome. Rev Neurol. 2003;35:453-457.

Hassan, A., Jan, M.M., Shabat, A.O. Topiramate for the treatment of intractable childhood epilepsy. Neurosciences. 2003;8:233-236.

Ritter, F., Glauser, T.A., Elterman, R.D. Effectiveness, tolerability, and safety of topiramate in children with partial onset seizures. Epilepsia. 2000;41:S82-S85.

Glauser, T.A., Levisohn, P.M., Ritter, F. Topiramate in Lennox–Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Epilepsia. 2000;41:S86-S90.

Herranz, J.L., Arteaga, R. Long-term efficacy and tolerance of topiramate in 44 children with resistant epilepsy. Rev Neurol. 1999;28:1052-1056.

Glauser, T.A., Miles, M.V., Tang, P. Topiramate pharmacokinetics in infants. Epilepsia. 1999;40:788-791.

Nieto-Barrera, M., Candau, R., Nieto-Jimenez, M. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9:590-594.

Takeoka, M., Holmes, G.L., Thiele, E. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42:387-392.

Fraunfelder, F.W., Fraunfelder, F.T., Keates, E.U. Topiramate-associated acute, bilateral, second angle-closure glaucoma. Ophthalmology. 2004;111:109-111.